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Abstract
Objective: To explore the capacity of human CD14
+CD16
++ and CD14
++CD16
- monocytes to phagocyte iron-oxide
nanoparticles in vitro.
Methods: Human monocytes were labeled with four different magnetic nanoparticle preparations (Ferumoxides, SHU 555C,
CLIO-680, MION-48) exhibiting distinct properties and cellular uptake was quantitatively assessed by flow cytometry,
fluorescence microscopy, atomic absorption spectrometry and Magnetic Resonance Imaging (MRI). Additionally we
determined whether cellular uptake of the nanoparticles resulted in phenotypic changes of cell surface markers.
Results: Cellular uptake differed between the four nanoparticle preparations. However for each nanoparticle tested,
CD14
++CD16
- monocytes displayed a significantly higher uptake compared to CD14
+CD16
++ monocytes, this resulted in
significantly lower T1 and T2 relaxation times of these cells. The uptake of iron-oxide nanoparticles further resulted in a
remarkable shift of expression of cell surface proteins indicating that the labeling procedure affects the phenotype of
CD14
+CD16
++ and CD14
++CD16
- monocytes differently.
Conclusion: Human monocyte subsets internalize different magnetic nanoparticle preparations differently, resulting in
variable loading capacities, imaging phenotypes and likely biological properties.
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Introduction
Monocytes originate from the bone marrow, and are released
into the circulation where they can circulate several days until they
extravasate and populate healthy and diseased tissues [1]. Upon
extravasation monocytes can differentiate and serve as a source to
replenish tissue resident macrophages and dendritic cells [2]. As
mediators both of innate and adaptive immunity they are involved
in tissue homeostasis and various diseases such as bacterial and
viral infections, cancer and atherosclerosis [2]. In order to study
various disease mechanisms by means of biomedical imaging, ex
vivo labeling of monocytes with various agents and subsequent
tracking of these cells has been performed [3]. Additionally, in vivo
phagocytosis of various nanoparticle imaging agents has been
utilized to characterize disease stages, e.g. to discriminate be-
tween benign or malignant neoplastic lesions [4,5] or to track
macrophage infiltration in autoimmune encephalitis and multiple
sclerosis [6,7]. Superparamagnetic iron-oxide based nanoparticles
are the most extensively studied materials used for either non-
specific labeling or specific targeting of cell surface receptors via
high-affinity ligands on functionalized nanoparticles [8]. Biocom-
patible magnetic nanoparticles are often classified by composition,
size, coating, crystallinity and manufacturing process. Preparations
,100nm are often lumped as ultrasmall SPIO (USIPO) and single
crystal nanoparticles as monocrystalline iron-oxide nanoparticles
(MION). Iron-only nanoparticles contain both Fe
2+ and Fe
3+ ions
in variable stochiometric ratios, e.g. Fe2
3+O3Fe
2+O [9]. To keep
the particles suspended, the core is surrounded by various coating
materials such as dextrans, modified dextrans or other polymers.
Magnetic nanoparticles shorten both the T1 and T2/T2*
relaxation with subsequent signal decrease in Magnetic Resonance
Imaging (MRI). The effects on signal intensity depend on particle
composition, particle size, concentration of particles within a given
imaging voxel and signal acquisition parameters. The magnetic
field strength has a non-linear influence on the obtained signal,
however with minor importance in clinical practice. Metz et al.
have analyzed the phagocytosis of various approved iron-oxide
contrast agents by human monocytes and optimized labeling
protocols [10]. Similarly Oude Engeberink et al. performed
labeling of freshly isolated human monocytes with SPIOs and
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as well as functional parameters after the labeling procedure [11].
However in both studies, labeling of monocytes has been
conducted in an unselective manner with no regard to different
monocyte subpopulations [10,11].
Monocyte heterogeneity is conserved in humans and mice
[1,12,13]. In the mouse, at least two monocyte subpopulations have
been identified with divergent functional properties [14,15]. While
Ly6C
++CD43
+ monocytes have been found to propagate disease
and promote inflammation, Ly6C
+CD43
++ monocytes attenuated
inflammation and areinvolved in tissue repair. Similarlyin humans,
at least two principal monocyte subsets have been identified that
can be distinguished by the expression of CD 14 and CD16:
CD14
++CD16
- monocytes and CD14
+CD16
++ monocytes. Al-
though some similarities have been identified between mice and
humans [12], a possible homology of the described subsets between
the different species is not clear yet. In humans, elevated serum
levels of CD14
+CD16
++ have been observed in coronary artery
disease, sepsis, HIV infection, kidney failure and cancer
[2,16,17,18,19,20,21]. The increasing evidence that monocyte
subsets play divergent roles in various human diseases has not been
taken into account in studies involving cell labeling and tracking
with MRI. We have previously shown that monocyte subsets have
different phagocytosis capacity for macromolecules and magnetic
nanoparticles [8]. In this study we investigate magnitude and effects
of cellular iron-oxide nanoparticle uptake by flow cytometry,
fluorescence microscopy, atomic absorption spectrometry and MR
imaging. Using the most salient nanomaterial with the highest
native cellular uptake, we perform selective phenotyping experi-
ments to assess possible alterations of cell surface proteins.
Materials and Methods
Isolation of human monocytes
The study protocol was approved by the institutional review
board at Harvard Medical School, Boston, MA. The institutional
review board specifically approved the use of human blood
specimens for the performed ex-vivo experiments. Whole blood
was obtained from healthy volunteers (8 male, 7 female, age 3764
years). All donors gave written and informed consent. Fresh whole
blood was drawn into heparinized collection tubes. To obtain
leukocyte suspensions, whole blood was diluted 1:1 with
Dulbecoo’s Phosphate Buffered Saline (DPBS) and 20 ml diluted
blood was overlaid on a 15 ml density gradient (Ficoll-Paque Plus,
density 1.077 g/ml, GE Healthcare, NJ) and centrifuged (20 min,
1600 rpm, 18uC). The mononuclear cell interphase was carefully
isolated and washed 3 times with DPBS. Resuspended cell
suspensions were counted using Trypan blue (Cellgro, Mediatech
Inc., Manassas, VA).
Phagocytosis assay
For the determination of differences in phagocytosis between
both monocyte subsets, yellow-green labeled latex beads were used
(Bead size 2.0 mm, Sigma, Saint Louis, MO). FACS-sorted
monocyte subsets where incubated at a cell/bead ratio of 1/25
(10
6 cells in 1ml final volume) for 4h at 37uC in RPMI 1640,
supplemented with 1% Penicillin/Streptomycin and 10% heat-
inactivated fetal calf serum (FCS). After incubation, free beads
were washed from the cell suspension 3 times and cells were
analyzed by flow cytometry using the appropriate filters.
Exposure of cells to magnetic nanoparticles
For our study, we used four different superparamagnetic iron-
oxide preparations. Two agents used in laboratory setting only:
CLIO-680, a fluorescent cross-linked iron oxide and MION-48,
prototype monocrystalline iron-oxide; as well as two clinically
approved agents:Ferumoxides (Feridex, Advanced Magnetics,USA)
as a prototype clinical SPIO and one clinical approved USPIO:
SHU 555C (Resovist S, Bayer Schering Pharma, Germany). The
particle characteristics are summarized in Table 1. All particles
displaya similartype of dextran surfacecoating,althoughthe density
(polymer/Fe) differs. CLIO-680 has already been evaluated for
targeting both human as well as murine monocyte subsets [8,15,22].
The two experimental agents (CLIO-680, MION-48) both fall into
the USPIO category, similar to the clinical approved SHU 555C. As
several studies have shown favorable uptake of SPIOs by monocytes
as compared to USPIOs we additionally chose a clinically approved
SPIO for labeling the monocyte subsets.
CLIO-680
CLIO-680 are fluorescently labeled cross-linked iron-oxide
nanoparticles used only in the experimental setting. Derived from
MION-47, they have similar superparamagnetic characteristics as
well as thick T10-dextran shell. In brief, MION particles are
reacted with the crosslinking agent epichlorohydrin, which
connects the partly free-floating dextran chains around the iron
core. Thereby the iron core becomes completely caged which
makes the particle chemically stable [23]. As the amino groups of
the dextran chains become functionalized and nucleophilic they
can be used for further conjugation, e.g. to fluorochromes or
transfection agents such as HIV-tat peptides or protamine, as
previously described [24]. To track the cellular processing of these
nanoparticles we attached amine reactive near-infrared fluoro-
chromes (VivoTag680, Perkin Elmer, Waltham, MA) to the
nanoparticles. Each particle of CLIO-680 contained ,11
molecules of dye and ,80 free amine groups. We have successfully
used CLIO-680 for targeting phagocytosis [8,15,22], by means of
MRI as well as optical imaging [22].
Table 1. Particle characteristics of the different iron-oxide nanoparticles.
Name Characteristic Mean Size (nm) Coating R1 (mM
21s
21)R 2 ( m M
21s
21)
CLIO-680
19,20 Experimental magnetofluorescent
nanoparticle
29 Dextran 28.8 (0.47T/37uC) 74.3 (0.47T/37uC)
MION-48
22 Experimental monocrystalline
nanoparticle
26 Dextran 32.4 (0.47T/37uC) 130.5 (0.47T/37uC)
Ferumoxides (Feridex)
8 Approved SPIO 80-150 Dextran 40.0 (0.47T/40uC) 160.0 (0.47T/40uC)
SHU 555C (Resovist S)
8 Approved USPIO 21 Dextran 24.0 (0.47T/37uC) 60.0 (0.47T/37uC)
doi:10.1371/journal.pone.0025197.t001
Monocyte Subsets Nanoparticles
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MION-48, a prototype monocrystalline iron-oxide nanoparti-
cle, is a further development of MION-47 with similar surface
properties but higher relaxivities. The preparation used for the
current experiments yielded a R2 relaxivity twice as high as
CLIO-680, increasing the susceptibility in T2 weighted imaging. It
is used in the experimental setting only; e.g. it has been successfully
applied for in vivo monitoring of angiogenesis [25].
Ferumoxides
Ferumoxides (Feridex I.V., Advanced Magnetics, USA) are
colloid based SPIO that are taken up by the reticuloendothelial
system and have been approved for liver imaging. The R1 and R2
relaxivities are 40.0 mM
21 s
21 and 160.0 mM21s 21 at 0.47T,
respectively. Ferumoxides are a heterogeneous in the size with
hydrodynamic diameters from 80 to 150 nm. They consist of non-
stoichiometric magnetite cores, also covered with a dextran T-10
layer. Blood pool half-life of Ferumoxides after i.v. injection is
about 6min. Ferumoxides are administered in patients at a dose of
838 mg Fe/kg [10].
SHU 555C
SHU 555 C (Resovist S, Bayer Schering Pharma AG) are USPIO
particles extracted from Ferucarbotran. The R1 and R2 relaxivities
are 24.0 mM21s21and 60.0 mM
21s
21 at 0.47T in blood plasma
at 40uC. The mean hydrodynamic size (including the hydrated
dextran coating in an aqueous environment) is about 21 nm. SHU
555 C is administered in patients at a maximal dose of 2234 mg
Fe/kg [10]. USPIOs have been successfully evaluated for the
differentiation of metastatic versus benign/inflammatory lymph
nodes [4], to characterize rupture prone atherosclerotic plaques [26]
and to track neoangiogenesis in different murine tumor models [27].
FACS sorted monocytes or unsorted leukocytes were plated at
10
5 cells/200 ml in a 96 well plate. Cell labeling with iron-oxide
nanoparticles was performed at concentration from 0 to 2000 mg
Fe/ml in 1640 RPMI for 2h, 37uC, humidified CO2 atmosphere.
After the incubation period, cell suspensions were washed 3 times
to separate labeled cells from unbound particles. For optical
assessment by flow cytometry, cells were additionally stained with
CD14 and CD16. After labeling, cells were counted again and cell
viability was assessed with trypan blue. As controls, non-labeled
FACS sorted monocyte subsets were used.
Flow cytometry
Cell suspensions were stained with the following antibodies (all
from BD Bioscience, unless otherwise stated) at a final concentra-
tion of 1:100: CD11b-APC-Cy7/ICRF44, CD14-PE/M5E2,
CD16 PE-Cy7/3G8, CCR2-Alexa-647/48607, CX3CR1-FITC/
2A91 (MBL International, Woburn, MA), HLA-DR-APC/L243,
CD163/GHI61, CD206/19.2, CD23/M-L233, CD120a/R1-B1.
Cell phenotyping was performed using a LSRII Flow Cytometer
(BD Bioscience, San Jose, CA) after appropriate compensations.
For cell sorting, cells were labeled with CD14/CD16 and flow-
sorted with a FACSAria (BD Bioscience, San Jose, CA). Purity of
each monocyte subset population was ,95% as determined by
post-FACS flow-cytometric assessment. For the detection of
fluorescent CLIO-680, the LSR II Flow Cytometer was equipped
with a 685/LP and 695/40BP filter. Flow cytometric data were
analyzed using FlowJo v.8.5.2 (Tree Star, Inc., Ashland, OR).
For morphologic characterizations, sorted cells were prepared
on slides by cytocentrifugation (Shandon Inc., Pittsburgh, PA) at
10xg for 5 min, and stained with HEMA-3 (Fischer Scientific,
Pittsburgh, PA).
Fluorescence microscopy
FACS sorted human monocytes were immobilized by sedimen-
tation for 1h on a poly-l-lysine coated coverslip (BD Biocoat, BD)
and adherent cells were fixed for 30min in phosphate-buffered
saline containing 3.7% paraformaldehyde (Sigma) and 0.2%
Triton-X 100 (Sigma).
Cells were blocked for 30min in 1% BSA at 37uC and thereafter
stained in blocking buffer supplemented with a FITC conjugated
mouse anti-clathrin antibody (BD Transduction Laboratories)
specific for the clathrin heavy chain at a dilution of 1:200 for 1 h.
The coverslips were washed three times in PBS and mounted onto a
glass slide using 10 ml of mounting media (VECTASHIELD H-
10000, Vector Laboratories). Fluorescence microscopy was per-
formedonaNikonEclipse80imicroscopeusinga60x/1.45objective
with oil immersion. For image acquisition a Hamamatsu C4742-95
digital camera connected to the IPLab (BD) softwarewas used. Image
analysis was performed using ImageJ v1.44 (http://rsbweb.nih.gov/
ij/). Specifically differential CLIO-680 update was determined by
assessing the mean grey values of the cytoplasm as a measure of
CLIO-680 uptake of a least 10 cells per preparation in the Cy5.5-
channel. Co-localization analysis of CLIO-680 and phagocytic
vesicles was performed using the ImageJ plugin ‘Co-localization’.
Spectrometry
Iron concentrations of FACS sorted monocyte subsets, labeled
with the various iron-oxide nanoparticles, and non-labeled
controls were quantified by atomic absorption spectrometry using
a polarized Zeeman atomic absorption spectrometer (Z-8200,
Hitachi, Japan). The cell pellets were dissolved with 1% sodium
dodecyl sulfate (SDS) buffer. For Fe-measurements, the spectro-
photometer was set to 248.3 nm and calibrated with six standards,
containing 5000–200,019 mg/l Fe in 0.05 M HCl. For quality
control, normal and abnormal lyphochek controls (Bio-Rad
Laboratories, Munich, Germany) were used.
MR imaging of labeled cells
FACS-sorted monocyte subsets were incubated with CLIO-680,
MION-48, Ferumoxides and SHU 555C at 100 mg Fe/ml. 10
5
labeled cells were resuspended in 300 ml sucrose gradient solution
(Ficoll-Paque Plus, density 1.077 g/ml, GE Healthcare, NJ) to
prevent sedimentation of cells during imaging [28]. The Ficoll-cell
suspension in Eppendorf tubes was subsequently embedded in a
water container, which minimizes susceptibility artifacts caused by
interfaces with air or plastic. Unlabeled monocyte subsets were used
as controls. MR imaging was performed on a 1.5T clinical imaging
system (Achieva, Philips Medical Systems, Best, Netherlands) with a
MAI wrist coil. For the simultaneous measurement of T1 and T2
the standard Philips MIX sequence was used. It consists of an
interleaved IR and SE sequence with both signals being read out
with multiple spin echoes. The echo trains serve to determine T2,
while the ratiosofthe IR toSEsignalslead to T1. Thesequenceand
its subsequent data evaluation has been described in detail [29]. A
3D sequence with 3 slices was used to minimize artifacts caused by
otherwise systematically smaller flip angles at the edges of 2D slices.
Only the central slice was used for parameter quantization.
Sequence parameters included TRIR 1500 ms, TI 100ms, TRSE
650 ms, TE 30*7ms, FOV 160687 mm, matrix 1926104, slice
thickness: 3 mm, in-plane resolution 0,8360.83 mm, bandwidth
613 Hz/pixel, Acquisition time: 19:08 min.
Statistical analysis
Data are expressed as Mean 6 SD. Multiple comparisons of
differences between the uptake of iron-oxide nanoparticles
Monocyte Subsets Nanoparticles
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tween the nanoparticles were performed by analysis of variance
(ANOVA). Statistical significance between the groups was
calculated by the f-test. To evaluate differences in the expression
of cell surface proteins before and after labeling, paired student’s t-
test was applied. A p-value ,0.05 was considered statistically
significant. Statistical analysis was performed with GraphPad
Prism 5.0a for Mac (DraphPad Software Inc. San Diego, CA).
Results
Flow Cytometry and Fluorescence Microscopy
In a first set of experiments we identified two major monocyte
subpopulations by flow cytometry and assessed their phagocytosis
capacity with both fluorescent beads as well as fluorescent
nanoparticles. Human monocytes were obtained from peripheral
blood of healthy volunteers by density-gradient centrifugation.
The procedure enriches mononuclear cells by removing neutro-
phils and other granulocytes. Monocytes (10–30 mm) are larger
than lymphocytes (5–15 mm) and can be identified by a distinct
forward scatter/side scatter profile (FSC/SSC) [8,13,21]. With
respect to the expression of CD14 and CD16, monocytes can be
divided into two major populations: CD14
++CD16
- monocytes,
which make up about ,85% of all monocytes, and a minor
population of CD14
+CD16
++ monocytes (Figure 1A). Upon 2h
incubation with fluorescent latex-beads, CD14
++CD16
- monocytes
display a significant higher bead uptake, assessed by the mean
fluorescent intensity (MFI), indicating a higher phagocytosis
Figure 1. Monocyte subsets display different capacity of phagocytosis, which results in divergent uptake of iron-oxide
nanoparticles. A) Flow cytometry dot plots of freshly isolated leucocytes from healthy donors. Monocytes are identified upon their FSC/SSC profile.
Monocytes subsets are identified by their CD14/CD16 expression profile. H&E stains show monocyte morphology. B) Phagocytosis assay: flow
cytometry histograms of both monocyte subsets after incubation with FITC-labeled latex beads for 2 h. Bar graph compares mean fluorescence
intensity of internalized FITC-beads between both subsets, p-value shows significant difference (student’s t-test). C) Bar graph depicts percentage of
positively labeled alive monocyte subsets after 2h incubation with increasing concentrations of fluorescently labeled iron-oxide nanoparticles (CLIO-
680), assessed by multi-color flow cytometry. D) Representative histogram shows fluorescence intensity of both monocyte subsets after labeling for
2 h with CLIO-680 at 100 mg Fe/ml. E) Quantitative immunofluorescence microscopy of FACS sorted monocytes after labeling with fluorescent iron-
oxide nanoparticles (CLIO-680). Green: Clathrin, Red: CLIO-680, Blue: DAPI/nuclear staining. For co-localization analysis (upper right panel) images
were taken under reproducible conditions and no additional enhancement was performed for the red and green channels. Fiducials indicate the red-
green signal intensities used for determination of co-localization. White-circled areas indicate co-localization of Clathrin and CLIO-680 signal. Bar
graph compares mean grey values of intracellular CLIO-680 signal between both subsets (from n=3 different experiments with .10 of each subset
analyzed per experiment).
doi:10.1371/journal.pone.0025197.g001
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++CD16
- monocytes as compared to their
CD14
+CD16
++ counterparts (Figure 1B). Subsequently we inves-
tigated the uptake of the fluorescent superparamagnetic nanopar-
ticle CLIO-680 by flow cytometry at different particle concen-
trations for 2h. At concentrations from 10–1000 mg Fe/ml a
significantly higher proportion of CD14
++CD16
- monocytes is
labeled with CLIO-680 as compared to the CD14
+CD16
++
monocytes (Figure 1C). Only at concentrations of 2000 mg Fe/ml
CD14
+CD16
++ monocytes are positively labeled at a comparable
degree. However, labeling concentrations above 100 mg Fe/ml are
entirely unphysiologic when compared to plasma concentration of
iron-oxide nanoparticles after i.v. administration [10]. Therefore,
subsequent labeling experiments were performed at iron concen-
trations of 100 mg Fe/ml. At 100 mg Fe/ml cell viability was
$98%, as determined by trypan blue staining. This is in
accordance with previous labeling studies that demonstrated that
only at concentrations .500 mg Fe/ml iron exerts relevant toxicity
to the incubated cells [10,11]. At 100 mg Fe/ml the two subsets
populations can be clearly discriminated from each other by a
different labeling efficiency (Figure 1D). The mechanism of
particle internalization is directly related to particle size. Particles
,200 nm are internalized via endocytosis and transported
intracellularly within clathrin-coated vesicles [30]. After labeling
FACS sorted monocyte subsets with fluorescent nanoparticles,
fluorescence of nanoparticles co-localized with clathrin fluores-
cence, indicating a clathrin dependent intracellular storage of the
superparamagnetic particles (Figure 1E).
Spectrometry
To quantify the nanoparticle uptake, FACS sorted monocyte
subsets were incubated with different nanoparticles at concentra-
tion of 100 mg Fe/ml. As particle uptake is both related to particle
size and surface coating we studied the particle uptake of two
experimental and two clinically approved iron-oxide particles
(Table 1). The amount of intracellular iron, representative for
particle uptake, was significantly higher in CD14
++CD16
-
monocytes (p=0.0015, ANOVA) as compared to the CD14
+CD16
++
monocytes (Figure 2). Intracellular iron-concentrations were signifi-
cantly different with regard to the labeling particle (p=0.0251,
ANOVA), with both CLIO-680 and MION-48 showing a higher
uptake as compared to the two clinical approved Ferumoxides and
SHU 555C. Iron-levels of non-labeled monocytes were below the
detection limit (of 100 ng Fe/ml cell suspension).
MR imaging
To determine if the different cellular uptake of nanoparticles
betweenCD14
++CD16
- and CD14
+CD16
++monocytestranslates to
imageable differences, we incubated FACS sorted monocytes with
the various nanoparticles for subsequent ex vivo MR imaging
(Figure 3). Increased nanoparticle uptake of the CD14
++CD16
-
monocytes indeed resulted in significant lower T1 (p=0.0006,
ANOVA) and T2 (p=0.0004, ANOVA) relaxation times for the
various particles. Also the particle type had impact on the T1
(p=0.006, ANOVA) and T2 (p=0.0025, ANOVA) relaxation
times, with both Ferumoxides and CLIO-680 leading to a more
severe drop in T1 and T2 relaxation time as compared to SHU
555C and MION-47. Mean relaxation times of non-labeled con-
trols were as followed: T1=2190643ms/2173649ms (CD16
++/
CD16
2), T2=841628ms/835630ms (CD16
++/CD16
2).
Phenotype alterations after cell labeling
An important aspect of nanoparticle uptake by mononuclear
phagocytes is whether the cell labeling affects their phenotype.
Therefore we assessed a preliminary set of cell surface markers
before and after incubation with the fluorescent nanoparticle
CLIO-680 to search for potential alterations of the cell phenotype
due to the labeling process. We studied the expression of cell
adhesion molecules (CD11b, CCR2, CX3CR1), HLA-DR as
marker for antigen presentation as well as markers expressed
during the differentiation of monocytes to macrophages (CD23,
CD163, CD206). Further, CD120a, the TNFa receptor was
analyzed as a marker indicating the susceptibility of monocytes to
inflammatory stimuli. After 2 h of incubation with CLIO-680 at
100 mg Fe/ml CD14
++CD16
- monocytes selectively up regulated
the CCL2 receptor while CD14
+CD16
++ monocytes down
regulated the fractalkine receptor CX3CR1. Both monocyte
subsets up regulated HLA-DR indicating an increased potential
to present processed antigens on their cell surface. In terms of
differentiation, CD14
+CD16
++ monocytes up regulated CD206,
while CD23 and CD163 showed no marked difference. While
CD120a expression was down regulated in CD14
+CD16
++
monocytes, it was expressed at significantly higher levels in
CD14
++CD16
- monocytes after labeling with CLIO-680 (Figure 4).
Discussion
To non-invasively study disease mechanisms by means of
Magnetic Resonance Imaging, labeling of human monocytes with
both positive contrast agents as well as superparamagnetic
nanoparticles has been performed [10,28,31]. Ex vivo labeled
human cells can be successfully reinjected into patients and
tracked with MRI [32]. The ex vivo labeling of human phagocytes
with subsequent reinjection and in vivo MR Imaging is expected
to enhance inflammatory or neoplastic lesions more specifically
than the pure contrast agent after i.v. injection. Reinjection of ex
vivo labeled monocytes could direct the contrast agents more
specifically to the pathologic target. This could solve current
problems of limited sensitivity of MR imaging and increase
contrast-to-noise ratio due to a limited background signal. Up to
Figure 2. Absolute quantification of intracellular iron content
in monocyte subsets by Zeeman atomic emission absorption
spectrometry. FACS sorted monocyte subsets were incubated with
four different iron-oxide nanoparticles (Ferumoxides, SHU 555C, CLIO-
680, MION-48) at 100 mg Fe/ml for 2 h. Differences in intracellular iron
contents between the subsets were assessed by ANOVA. P-values
indicate significant differences in intracellular iron-content between the
monocyte subsets. n=3-5 for each bar graph. Iron levels of non-labeled
control monocytes were below the detection limit.
doi:10.1371/journal.pone.0025197.g002
Monocyte Subsets Nanoparticles
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unselectively without respect to their heterogeneity [10,11].
However, as recent work on monocyte heterogeneity has revealed
monocyte subpopulations that perpetuate disease and promote
inflammation, while other monocyte subsets promote healing and
resolve inflammation [1,2,14,15], selective labeling of these subsets
will be important for targeting specific disease mechanisms by MRI.
We have previously shown that human monocyte subsets
display different capacity of phagocytosis [8] and these results were
recently confirmed by Cros et al. [33]. Here we further exploit
these properties and show that CD14
++CD16
- monocytes show a
higher uptake of both experimental and clinically approved iron-
oxide contrast agents and that this increased uptake leads to
shorter T1 and T2 relaxation times at 1.5T. The iron uptake of
the two clinically approved iron-oxide nanoparticles, quantified by
Zeeman spectrometry, was comparable to the values reported by
Metz et al [10]. The cellular uptake of MION-48 by both
monocytes subsets was higher than the previously reported uptake
of MION-46 by cultured peritoneal macrophages [34], which is
attributed to the variant differentiation stage of the phagocytes as
well as different particle characteristics of MION-46 versus
MION-48. In general, differences between the different agents
are attributed to particle size and surface coating, opsonization as
well as surface charge [10,35].
Additionally intracellular particle compartmentalization influenc-
es the relaxivity. Therefore no linear relationship can be assumed
between the amount of particle uptake and relaxivity [9]. Using a
magnetofluorescent nanoparticle we demonstrate that the internal-
ized iron-oxide particle (CLIO-680) co-localizes with clathrin-coated
vesicles. Also in our study the amount of intracellular nanoparticles
measured by atomic absorption spectrometry did not directly
translate to the observed relaxation times. As all of the four particles
tested were similarly dextran coated, this is mainly attributed to
particle size, opsonization and cellular compartmentalization.
Several studies have demonstrated that endocytosis of nanoparticles
is highly dependent on the particle size [36]. Regarding the particle
size two important aspects have to be considered. First, there is an
inherent polydispersity within any given batch of nanoparticles and
some nanoparticle formulations, e.g. Ferumoxides are quite
heterogeneous in size. Secondly, although nanoparticles retain a
certain size after synthesis, they may aggregate during in-vitro and
in-vivo studies into fairly different shapes and sizes that may further
alter the endocytosis of the particle. Differences in opsonization also
have to be taken into account when phagocytosis of nanomaterials
by the targeted cells is discussed, however only preliminary data exist
on how the complement system interacts with superparamagnetic
nanoparticles. In this context Beduneau et al. demonstrated that
altering opsonization by coupling of IgG to the surface of SPIOs
Figure 3. Different degree of labeling with variant iron-oxide nanoparticles results in different alteration of T1 and T2 relaxation
rates between the monocyte subsets. A) Representative examples of phantom imaging of FACS sorted nanoparticle-labeled monocyte subsets
with a clinical 1.5T MRI system. Phantom plots show NIH-color coded transversal sections through the samples tubes containing the labeled
monocyte subsets embedded in Ficoll solution to prevent sedimentation during imaging. B) Graphs show corresponding T1 and T2 relaxation times
obtained from phantom experiments (graphs show mean 6 SD from 3 different experiments). After labeling with variant iron-oxide nanoparticles
(Ferumoxides, SHU 555C, CLIO-680, MION-48) at 100 mg Fe/ml for 2h, the CD16
- subset is characterized by shorter T1 (p=0.0006, ANOVA) and T2
(p=0.0004, ANOVA) relaxation times as compared to CD16
++ monocytes. Mean relaxation times of non-labeled controls were as followed:
T1=2190643 ms/2173649 ms (CD16
++/CD16
-), T2=841628 ms/835630 ms (CD16
++/CD16
-).
doi:10.1371/journal.pone.0025197.g003
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enhancement of lymphoid tissue by high-field MRI [37]. Surface
charge of the particles is another factor influencing the interaction
with cell-surface proteins and further uptake. The surface charge is
mainly dependent on the coating material, in our case T10 dextran.
Thereforedifferent surface charge is not seen as major reason for the
different cellular uptake in our study. Yet it is known that functional
groups attached to the nanoparticle surface can further modify
nanoparticle properties [36]. Thus, it cannot be excluded that the
attachment of the NIRF fluorochrome to the CLIO particles in our
study alters the particle internalization and compartmentalization.
This may explain the fact that compared to MION-48 the uptake
CLIO-680 is slightly higher and that the decrease in T1 and T2
relaxivity of CLIO-680 labeled monocyte subsets is markedly higher
as compared to MION-48.
The results obtained in this study can not be necessarily expanded to
particles with other surface coatings. The different surface properties,
e.g. of polyvinyl alcohol or dopamine-polyethylene-glycol coating is
known to alter the cell-particle interaction and subsequent internali-
zation of the particle [36]. However for all particles investigated,
CD14
++CD16
- monocytes showed higher intracellular iron concen-
trations compared to CD14
+CD16
++ monocytes and T1 and T2
relaxation times were lower for all tested agents in CD14
++CD16
-
monocytes compared to their CD14
+CD16
++ counterparts.
As previous studies in humans have demonstrated, blood levels
of CD14
+CD16
++ monocytes are elevated in chronic diseases. The
reason for the elevated CD14
+CD16
++ levels in these inflamma-
tory conditions is not entirely clear yet. However previously
published work suggests that the CD14
+CD16
++ monocytes are
active in production of pro-inflammatory cytokines (e.g. TNFa
and IL1b) and chemokines (e.g. CCL3) and exhibit a higher
potency in antigen presentation, whereas the CD14
++CD16
-
monocytes with increased phagocytosis capacity are involved in
tissue repair [33,38].
Labeling of monocytes with iron-oxide based nanoparticles may
affect their phenotype as well as certain functional properties. Oude
Engberink studied the migratory capacity after labeling of
monocytes with SPIOs and USPIOs as well as production of
certain cytokines, such as IL1 and IL6. Neither the migratory
capacity, nor the production of the investigated cytokines was
affected by the labeling procedure, assessed directly after incubation
[11]. Yet, changes of the cellular phenotype may still occur.
Additional to the uptake experiments performed we analyzed a
preliminary set of cell surface markers before and after labeling the
cells with iron-oxide nanoparticles. Although the cell labeling
procedure consumes a limited amount of time, in our case 2h, both
the artificial labeling environment as well as the particle endocytosis
itself may significantly affect the expression of cell surface proteins.
Figure 4. Alteration of specific phenotypic markers after incubation with fluorescent iron-oxide nanoparticles compared between
the CD16
- monocyte and the CD16
++ monocyte. Sorted monocytes were incubated with CLIO-680 at 100 mg Fe/ml for 2h and subsequently
analyzed by flow cytometry. Markers important for monocytes to enter the target tissue (CD11b, CCR, CX3CR1), to differentiate (CD23, CD163,
CD120a, CD206) and to present antigens (HLA-DR) are investigated. Mean fluorescence intensities of recorded events are shown 6 SD (from 3
different experiments). Statistically significant up or down regulation of surface proteins, if present, is indicated within each graph (paired students
t-test).
doi:10.1371/journal.pone.0025197.g004
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the markers tested. Remarkably, changes in the expression of cell
adhesion molecules were observed. While CD14
++CD16
- mono-
cytes up regulated the CCL2 receptor, CD14
+CD16
++ monocytes
down regulated the fractalkine receptor CX3CR1. Both molecules
are important for monocytes to adhere to the endothelium and
extravasate into the target tissue [39,40]. An up regulation of these
adhesion molecules may facilitate tissue entry while down regula-
tion may aggravate it. Both monocyte subsets increase their
expression of HLA-DR after incubation with iron-oxide nanopar-
ticles, which indicates a shift towards antigen presenting cells.
This is not surprising, as phagocytosis is regularly followed by
increased antigen presentation [41]. However a shift of monocytes
towards APC induced by the labeling procedure may change
the physiologic course, monocytes take on their route to tissue
repair and homeostasis and prime the labeled cells towards a
certain commitment. Increased expression levels of the mannose
receptor CD206, which is an important mediator of macro-
phage cell migration, demonstrates a selective differentiation of
CD14
+CD16
++ monocytestowards themacrophage lineage already
after two hours of in-vitro cell labeling, while CD14
++CD16
-
monocytesdidnotaltertheirexpression ofCD206.Upregulationof
the TNFa receptor CD120a in CD14
++CD16
- monocytes during
the labeling procedure makes the CD14
++CD16
- monocytes more
susceptible to inflammatory stimuli mediated by TNFa. Although
this set of phenotypic markers only is a very limited selection, the
current results demonstrate that even the short ex vivo labeling
procedure alters the phenotype of incubated naı ¨ve monocytes and,
that the up or down regulation of these markers differs between the
two main subsets.
The revealed differential endocytosis capacity of the monocyte
subsets has diagnostic potential, which goes beyond the previous
published work on unselective labeling of monocytes. Monocyte
subsets continue to emerge as important mediators of inflamma-
tion and tissue homeostasis with certain subsets attenuating
disease, others promoting inflammation [1,2,38]. Targeting of
certain inflammatory diseases with re-injected ex vivo labeled
monocytes has been proposed as a novel non-invasive diagnostic
tool. Both the efficiency as well as the specificity will be increased
when only specific monocyte subsets are used, that are particularly
involved in the disease process and thus preferentially recruited to
the site of inflammation. Therefore the labeling protocols will have
to be optimized for the specific monocyte subsets. To take
advantage of labeled monocyte subpopulations as more specific
disease reporters, the detailed roles of monocyte subsets in certain
diseases has be to further elucidated.
In addition to their diagnostic potential, monocytes loaded with
certain nanoparticles have been proposed as potential carriers to
enhance drug delivery [37]. Monocytes that incorporated nano-
sized drug-carriers could act as Trojan horses by crossing e.g. the
blood-brain barrier and enabling drug delivery [42]. In this
context it may also be favorable to use specific monocyte subsets
that achieve a higher nanoparticle load and exhibit a facilitated
tissue-entry to the target site.
The current study investigated the uptake of various iron-oxide
nanoparticles by monocyte subsets from healthy humans as well as
phenotypic changes induced by the labeling procedure. Further
labeling experiments will have to focus on labeling monocytes
from diseased patients. Especially in patients with certain
inflammatory conditions such as atherosclerosis, multiple sclerosis
or infectious diseases, activated monocytes may significantly alter
their endocytosis capacity resulting in different loading capacities.
Additionally, the specific roles of monocyte subsets in these
diseases has be further investigated to being able to use monocyte
subsets as imaging reporters in clinical radiology.
In summary, this study shows that the two main subsets of
human monocytes differentially take up iron-oxide based nano-
particles which leads to different T1 and T2 relaxation times when
the cells are investigated ex vivo. The specific labeling of the
human subtypes of mononuclear phagocytes will have impact on
both experimental and clinical trials working with cell labeling of
human phagocytes.
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